Stockscreener 앱 받기
0.394
0.93%
-0.0037
시간 외 거래:
.39
-0.004
-1.02%
전일 마감가:
$0.3977
열려 있는:
$0.3955
하루 거래량:
2.36M
Relative Volume:
0.17
시가총액:
$62.70M
수익:
$10.00M
순이익/손실:
$-29.47M
주가수익비율:
-1.97
EPS:
-0.2
순현금흐름:
$-21.55M
1주 성능:
-6.41%
1개월 성능:
-25.25%
6개월 성능:
-77.36%
1년 성능:
-84.37%
1일 변동 폭
$0.381
$0.4199
1주일 범위
$0.381
$0.4543
52주 변동 폭
$0.20
$3.05
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
명칭
Mereo Biopharma Group Plc Adr
전화
4403330237300
주소
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.394 | 63.29M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.05 | 123.82B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
784.28 | 81.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
816.95 | 52.00B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.36 | 44.14B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
352.23 | 40.83B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-30 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-03-27 | 개시 | JP Morgan | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-06-13 | 개시 | Robert W. Baird | Outperform |
| 2023-10-13 | 재개 | BTIG Research | Buy |
| 2022-08-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-05-05 | 개시 | BTIG Research | Buy |
| 2021-04-05 | 개시 | Needham | Buy |
모두보기
Mereo Biopharma Group Plc Adr 주식(MREO)의 최신 뉴스
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
Mereo BioPharma Group plcSponsored ADR $MREO Stock Holdings Raised by Aberdeen Group plc - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - ChartMill
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - marketscreener.com
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - Finviz
Mereo BioPharma Faces Securities Litigation - Intellectia AI
MREO SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Mereo BioPharma Group plc Sued for Securities Law ViolationsInvestors Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsMREO - ChartMill
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
MREO Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Mereo BioPharma Group plc - Barchart.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Chartmill
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Mereo BioPharma Group plc Securities Class Action Lawsuit - Chartmill
Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Given Average Recommendation of “Hold” by Brokerages - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Mereo BioPharma Group plc – MREO - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - ChartMill
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo Biopharma Group Plc Adr (MREO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.68%
자본화:
|
볼륨(24시간):